Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study.
10.1016/j.joim.2020.10.002
- Author:
Xing ZHANG
1
;
Yan XUE
1
;
Xuan CHEN
1
;
Jia-Min WU
1
;
Zi-Jian SU
1
;
Meng SUN
1
;
Lu-Jiong LIU
1
;
Yi-Bao ZHANG
1
;
Yi-le ZHANG
1
;
Gui-Hua XU
1
;
Miao-Yan SHI
1
;
Xiu-Ming SONG
1
;
Yun-Fei LU
2
;
Xiao-Rong CHEN
2
;
Wei ZHANG
3
;
Qi CHEN
4
Author Information
1. Department of Respiratory Disease, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
2. Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
3. Department of Respiratory Disease, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: zhangw1190@sina.com.
4. Department of Respiratory Disease, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: chenqiywl@shutcm.edu.cn.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
COVID-19 diagnostic testing;
Coronavirus disease 2019;
Negative conversion rate;
Tanreqing Capsule
- MeSH:
Adult;
Antiviral Agents/therapeutic use*;
COVID-19/pathology*;
Capsules;
DNA, Viral/analysis*;
Drugs, Chinese Herbal/therapeutic use*;
Feces/virology*;
Female;
Humans;
Length of Stay;
Lymphocyte Count;
Male;
Medicine, Chinese Traditional/methods*;
Middle Aged;
Retrospective Studies;
SARS-CoV-2/genetics*;
Severity of Illness Index;
Treatment Outcome;
Young Adult
- From:
Journal of Integrative Medicine
2021;19(1):36-41
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019 (COVID-19). Tanreqing Capsule (TRQC) was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center. This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.
METHODS:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19; patients were treated with TRQC in one designated hospital. The treatment and control groups consisted of 25 and 57 cases, respectively. The treatment group was given TRQC orally three times a day, three pills each time, in addition to conventional Western medicine treatments which were also administered to the control group. The clinical efficacy indicators, such as the negative conversion time of pharyngeal swab nucleic acid, the negative conversion time of fecal nucleic acid, the duration of negative conversion of pharyngeal-fecal nucleic acid, and the improvement in the level of immune indicators such as T-cell subsets (CD3, CD4 and CD45) were monitored.
RESULTS:COVID-19 patients in the treatment group, compared to the control group, had a shorter negative conversion time of fecal nucleic acid (4 vs. 9 days, P = 0.047) and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid (0 vs. 2 days, P = 0.042). The level of CD3
CONCLUSION:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group, illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19. The underlying mechanism may be related to the improved levels of the immune indicator CD3
